Peptide Clinical Trial Tracker
See which peptides are being tested in people right now: how many trials are active, the most advanced phase, who sponsors them, and when results are expected.
38 peptides
SemaglutideMetabolic234active112recruitingPhase 4top active phase532ever registeredApproved Medicine
Showing 4 of 234 active trials, most advanced phase first.
| Trial | Phase | Status | Sponsor | Enrolment | Primary completion |
|---|---|---|---|---|---|
| Semaglutide [dose] Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE)NCT07859150 · Morbid Obesity | Phase 4 | Not yet recruiting | General Committee of Teaching Hospitals and Institutes, Egypt | 104 | 2029-04 |
| Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 DiabetesNCT06706284 · Spinal Cord Injuries, Type 2 Diabetes | Phase 4 | Recruiting | Marzieh Salehi | 50 | 2028-09-01 |
| Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight GainNCT07859163 · Morbid Obesity | Phase 4 | Not yet recruiting | General Committee of Teaching Hospitals and Institutes, Egypt | 100 | 2029-04 |
| Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric SurgeryNCT07859176 · Morbid Obesity | Phase 4 | Not yet recruiting | General Committee of Teaching Hospitals and Institutes, Egypt | 100 | 2028-04 |
Read the Semaglutide profile →Search ClinicalTrials.gov ↗
Search terms: semaglutide.
TirzepatideMetabolic136active74recruitingPhase 4top active phase211ever registeredApproved Medicine
Showing 4 of 136 active trials, most advanced phase first.
| Trial | Phase | Status | Sponsor | Enrolment | Primary completion |
|---|---|---|---|---|---|
| The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With ObesityNCT07218445 · Obesity, Menopause Hot Flashes | Phase 4 | Recruiting | Mayo Clinic | 40 | 2027-09-18 |
| GLP-1s to Enhance Lasting Optimal WeightNCT06861439 · Obesity | Phase 4 | Active, not recruiting | Wake Forest University Health Sciences | 40 | 2027-10-30 |
| Sequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)NCT06854614 · Obesity | Phase 4 | Active, not recruiting | The Cleveland Clinic | 150 | 2027-04-28 |
| A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)NCT06864026 · Psoriatic Arthritis, Overweight or Obesity | Phase 4 | Active, not recruiting | Eli Lilly and Company | 200 | 2027-08 |
Read the Tirzepatide profile →Search ClinicalTrials.gov ↗
Search terms: tirzepatide, LY3298176.
OxytocinReproductive62active44recruitingPhase 4top active phase606ever registeredApproved Medicine
Showing 4 of 62 active trials, most advanced phase first.
| Trial | Phase | Status | Sponsor | Enrolment | Primary completion |
|---|---|---|---|---|---|
| Carbetocin Monotherapy Versus Carbetocin Plus Oxytocin Infusion in Elective Cesarean Delivery: A Non-Inferiority TrialNCT07636421 · Postpartum Hemorrhage, Uterine Atony, Cesarean Section | Phase 4 | Recruiting | Mansoura University | 332 | 2028-04 |
| Effect of Intravenous Oxytocin on Post Dural Puncture Headache After Caesarean SectionsNCT07853924 · Post Dural Puncture Headache | Phase 4 | Not yet recruiting | Assiut University | 100 | 2027-09 |
| The Stimulation To Induce Mothers StudyNCT05079841 · Oxytocin, Labor Pain, Induction of Labor Affected Fetus / Newborn | Phase 4 | Active, not recruiting | Yale University | 933 | 2028-11 |
| Oxytocin Bolus Versus Infusion in High-Risk Patients Undergoing Elective Cesarean Section (INBOX-HR)NCT07688512 · Postpartum Hemorrhage, Uterine Atony, Uterine Atony With Hemorrhage | Phase 4 | Not yet recruiting | Stony Brook University | 180 | 2028-08 |
Read the Oxytocin profile →Search ClinicalTrials.gov ↗
Search terms: oxytocin.
MazdutideMetabolic24active9recruitingPhase 4top active phase44ever registeredInvestigational
Showing 4 of 24 active trials, most advanced phase first.
| Trial | Phase | Status | Sponsor | Enrolment | Primary completion |
|---|---|---|---|---|---|
| Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)NCT07718126 · Metabolic Dysfunction-Associated Steatohepatitis, Hepatic Steatosis, Living Liver Donors | Phase 4 | Recruiting | West China Hospital | 60 | 2029-02-28 |
| Mazdutide for Weight Management and Gout in Adults With ObesityNCT07824895 · Gout, Obesity (BMI>30), Hyperuricemia | Phase 4 | Not yet recruiting | Hongwei Jiang | 30 | 2027-12-31 |
| Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or ObesityNCT07657676 · Obesity & Overweight, Coronary Heart Disease | Phase 4 | Not yet recruiting | China National Center for Cardiovascular Diseases | 116 | 2027-12-31 |
| QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic NephropathyNCT07775846 · Type 2 Diabetic Kidney Disease | Phase 4 | Not yet recruiting | Huijie Zhang | 820 | 2029-02-28 |
Read the Mazdutide profile →Search ClinicalTrials.gov ↗
Search terms: mazdutide, IBI362, LY3305677.
OctreotideGrowth Hormone Axis21active9recruitingPhase 4top active phase197ever registeredApproved Medicine
Showing 4 of 21 active trials, most advanced phase first.
| Trial | Phase | Status | Sponsor | Enrolment | Primary completion |
|---|---|---|---|---|---|
| Hoffa's Fat Pad Impingement (HFPI)NCT07255248 · Hoffa's Fat Pad Impingement | Phase 4 | Recruiting | Boston Children's Hospital | 62 | 2027-11-01 |
| Octreotide vs. Splenic Artery Ligation for Portal Flow Modulation in Living Donor Liver Transplants (SCALOP Trial)NCT06974344 · Small-for-Size Syndrome | Phase 4 | Not yet recruiting | King Faisal Specialist Hospital & Research Center | 80 | 2030-05-01 |
| Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA TherapyNCT05477576 · GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease | Phase 3 | Active, not recruiting | RayzeBio, Inc. | 343 | 2026-12 |
| Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine TumorNCT00569127 · Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm | Phase 3 | Active, not recruiting | National Cancer Institute (NCI) | 427 | 2015-01-01 |
Read the Octreotide profile →Search ClinicalTrials.gov ↗
Search terms: octreotide.
LiraglutideMetabolic20active12recruitingPhase 4top active phase379ever registeredApproved Medicine
Showing 4 of 20 active trials, most advanced phase first.
| Trial | Phase | Status | Sponsor | Enrolment | Primary completion |
|---|---|---|---|---|---|
| Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)NCT03883412 · Type2 Diabetes | Phase 4 | Recruiting | University of Virginia | 60 | 2027-06 |
| Use of Liraglutide in Children Aged 6 to 12 Years With Severe ObesityNCT07590219 · Severe Obesity, Cardiovascular Function, Liraglutide | Phase 4 | Active, not recruiting | University of Sao Paulo General Hospital | 30 | 2027-04 |
| Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic SyndromeNCT04575844 · Metabolic Syndrome | Phase 4 | Recruiting | University of Virginia | 80 | 2027-04-30 |
| Liraglutide Effect in Atrial FibrillationNCT03856632 · Atrial Fibrillation | Phase 4 | Active, not recruiting | University of Miami | 60 | 2026-12-31 |
Read the Liraglutide profile →Search ClinicalTrials.gov ↗
Search terms: liraglutide.
VasopressinMetabolic19active14recruitingPhase 4top active phase98ever registeredApproved Medicine
Showing 4 of 19 active trials, most advanced phase first.
| Trial | Phase | Status | Sponsor | Enrolment | Primary completion |
|---|---|---|---|---|---|
| Intracervical VasopressinNCT07102615 · Retained Products of Conception | Phase 4 | Recruiting | Prisma Health-Upstate | 50 | 2026-12-01 |
| Early Versus Late Adjunctive Vasopressin in Septic ShockNCT06709573 · Sepsis, Septic Shock | Phase 4 | Recruiting | The Cleveland Clinic | 300 | 2027-05-01 |
| Vasoactive Drugs in Intensive Care UnitNCT02118467 · Shock | Phase 4 | Recruiting | University of Chicago | 836 | 2026-10-01 |
| Inotropic Effects of Vasopressin Versus Noradrenaline In Patients With Vasoplegic Syndrome After Cardiac SurgeryNCT06934798 · Vasoplegic Syndrome of Cardiac Surgery | Phase 4 | Recruiting | University of Sao Paulo | 350 | 2025-07-30 |
Read the Vasopressin profile →Search ClinicalTrials.gov ↗
Search terms: vasopressin.
CagrilintideMetabolic18active11recruitingPhase 3top active phase44ever registeredInvestigational
Showing 4 of 18 active trials, most advanced phase first.
| Trial | Phase | Status | Sponsor | Enrolment | Primary completion |
|---|---|---|---|---|---|
| Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With CagrilintideNCT07220759 · Overweight, Obesity, Type 2 Diabetes | Phase 3 | Active, not recruiting | Novo Nordisk A/S | 330 | 2027-05-12 |
| A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightNCT07253285 · Overweight, Obesity | Phase 3 | Recruiting | Novo Nordisk A/S | 460 | 2030-03-20 |
| Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to CagrisemaNCT07817251 · Diabetes Mellitus, Type 2 | Phase 3 | Recruiting | Novo Nordisk A/S | 210 | 2027-06-09 |
| A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightNCT05567796 · Obesity | Phase 3 | Active, not recruiting | Novo Nordisk A/S | 3,400 | 2024-10-30 |
Read the Cagrilintide profile →Search ClinicalTrials.gov ↗
Search terms: cagrilintide, CagriSema.
GlucagonMetabolic17active6recruitingPhase 4top active phase134ever registeredApproved Medicine
Showing 4 of 17 active trials, most advanced phase first.
| Trial | Phase | Status | Sponsor | Enrolment | Primary completion |
|---|---|---|---|---|---|
| Post-Prandial Carbohydrate Metabolism in Individuals With and Without Post-Bariatric Surgery Hypoglycemia (PBH)NCT07818707 · Hypoglycemia, Hypoglycemia, Reactive, Bariatric Surgery | Phase 4 | Recruiting | Joslin Diabetes Center | 40 | 2027-01 |
| The Postprandial Hypo-Avoid StudyNCT07427251 · Type 1 Diabetes Mellitus | Phase 4 | Recruiting | Steno Diabetes Center Copenhagen | 18 | 2027-05-01 |
| Glucagon Dose-Response in Patients With Post-Bariatric HypoglycemiaNCT06986603 · Hypoglycemia, Hypoglycemia, Reactive, Bariatric Surgery | Phase 4 | Active, not recruiting | Joslin Diabetes Center | 28 | 2026-06-01 |
| Studies of Insulin and Glucagon Action in the LiverNCT07300982 · Diabetes (DM) | Phase 1/Phase 2 | Not yet recruiting | Duke University | 40 | 2029-12 |
Read the Glucagon profile →Search ClinicalTrials.gov ↗
Search terms: glucagon.
DulaglutideMetabolic12active6recruitingPhase 4top active phase87ever registeredApproved Medicine
Showing 4 of 12 active trials, most advanced phase first.
| Trial | Phase | Status | Sponsor | Enrolment | Primary completion |
|---|---|---|---|---|---|
| GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac SurgeryNCT06324461 · Myocardial Injury | Phase 4 | Recruiting | The University of Hong Kong | 372 | 2028-12-31 |
| Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney DiseaseNCT07537088 · T2DM (Type 2 Diabetes Mellitus), CKD - Chronic Kidney Disease | Phase 4 | Not yet recruiting | First Affiliated Hospital of Wannan Medical College | 468 | 2027-04 |
| A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesNCT07668336 · Diabetes Mellitus, Type 2 | Phase 3 | Not yet recruiting | Eli Lilly and Company | 170 | 2030-03 |
| A Study of Dulaglutide (LY2189265) [dose] and [dose] in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)NCT06739122 · Type 2 Diabetes | Phase 3 | Recruiting | Eli Lilly and Company | 55 | 2027-12 |
Read the Dulaglutide profile →Search ClinicalTrials.gov ↗
Search terms: dulaglutide.
RetatrutideMetabolic11active2recruitingPhase 3top active phase33ever registeredInvestigational
Showing 4 of 11 active trials, most advanced phase first.
| Trial | Phase | Status | Sponsor | Enrolment | Primary completion |
|---|---|---|---|---|---|
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)NCT07165028 · Metabolic Dysfunction-Associated Steatotic Liver Disease | Phase 3 | Recruiting | Eli Lilly and Company | 4,500 | 2030-08 |
| The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390 · Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | Phase 3 | Active, not recruiting | Eli Lilly and Company | 10,000 | 2029-02 |
| Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)NCT06260722 · Diabetes Mellitus, Type 2 | Phase 3 | Active, not recruiting | Eli Lilly and Company | 1,250 | 2026-08-27 |
| A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainNCT07035093 · Obesity, Overweight, Chronic Low Back Pain (CLBP) | Phase 3 | Active, not recruiting | Eli Lilly and Company | 586 | 2027-09 |
Read the Retatrutide profile →Search ClinicalTrials.gov ↗
Search terms: retatrutide, LY3437943.
SurvodutideMetabolic10active4recruitingPhase 3top active phase35ever registeredInvestigational
Showing 4 of 10 active trials, most advanced phase first.
Read the Survodutide profile →Search ClinicalTrials.gov ↗
Search terms: survodutide, BI 456906.
TeriparatideOther10active3recruitingPhase 4top active phase123ever registeredApproved Medicine
Showing 4 of 10 active trials, most advanced phase first.
| Trial | Phase | Status | Sponsor | Enrolment | Primary completion |
|---|---|---|---|---|---|
| Combined Anabolic TherapyNCT06558188 · Osteoporosis, Postmenopausal, Osteoporosis | Phase 4 | Recruiting | Massachusetts General Hospital | 50 | 2027-11-02 |
| Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone TurnoverNCT05151484 · Age-Related Osteoporosis | Phase 4 | Active, not recruiting | Madhumathi Rao | 60 | 2027-01-31 |
| Precision Medicine Approach for Osteoporosis - Follow Up StudyNCT06264609 · Osteoporosis | Phase 4 | Enrolling by invitation | Paul F Netzel | 40 | 2029-12-31 |
| Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Chronic Kidney DiseaseNCT04522622 · Adynamic Bone Disease, Chronic Kidney Diseases, Cardiac Disease | Phase 4 | Recruiting | Ditte Hansen | 48 | 2026-09-01 |
Read the Teriparatide profile →Search ClinicalTrials.gov ↗
Search terms: teriparatide.
Thymosin Alpha-1Immune10active6recruitingPhase 2top active phase37ever registeredUnapproved
Showing 4 of 10 active trials, most advanced phase first.
| Trial | Phase | Status | Sponsor | Enrolment | Primary completion |
|---|---|---|---|---|---|
| Study of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal CancerNCT07780721 · Esophageal Cancer | Phase 2 | Not yet recruiting | The Affiliated Hospital of Putian University | 31 | 2028-08-01 |
| Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced MelanomaNCT07644897 · Melanoma, Immune-related Adverse Event, Immune Checkpoint Inhibitor | Phase 2 | Recruiting | Sun Yat-sen University | 55 | 2027-05-30 |
| Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction AdenocarcinomaNCT06461910 · Gastric Cancer, Esophagogastric Junction Adenocarcinoma | Phase 2 | Recruiting | Zekuan Xu | 30 | 2026-01-28 |
| Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal CancerNCT06056804 · Locally Advanced Rectal Cancer | Phase 2 | Active, not recruiting | Beijing Friendship Hospital | 20 | 2024-12-01 |
Read the Thymosin Alpha-1 profile →Search ClinicalTrials.gov ↗
Search terms: thymosin alpha 1, thymalfasin, Zadaxin.
LanreotideGrowth Hormone Axis6active3recruitingPhase 3top active phase72ever registeredApproved Medicine
Showing 4 of 6 active trials, most advanced phase first.
| Trial | Phase | Status | Sponsor | Enrolment | Primary completion |
|---|---|---|---|---|---|
| Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA TherapyNCT05477576 · GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease | Phase 3 | Active, not recruiting | RayzeBio, Inc. | 343 | 2026-12 |
| Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine TumorsNCT06878664 · Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs) | Phase 3 | Recruiting | Grupo Espanol de Tumores Neuroendocrinos | 166 | 2029-01 |
| A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NETNCT05050942 · Gastro-enteropancreatic Neuroendocrine Tumor | Phase 3 | Active, not recruiting | Camurus AB | 332 | 2026-11 |
| Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic FistulaNCT06807437 · Pancreatic Carcinoma, Pancreatic Neoplasm | Phase 3 | Recruiting | SWOG Cancer Research Network | 274 | 2027-11-01 |
Read the Lanreotide profile →Search ClinicalTrials.gov ↗
Search terms: lanreotide.
SetmelanotideMetabolic5active2recruitingPhase 4top active phase25ever registeredApproved Medicine
Showing 4 of 5 active trials, most advanced phase first.
| Trial | Phase | Status | Sponsor | Enrolment | Primary completion |
|---|---|---|---|---|---|
| Real-World Effects of MC4R Agonist Therapy in BBS and Severe Genetic ObesityNCT07674290 · Bardet Biedl Syndrome (BBS), Bardet Biedl Syndrome, Bardet-Biedl Syndrome (BBS) | Phase 4 | Recruiting | Tom Hühne | 200 | 2030-12-31 |
| A Trial of Setmelanotide in Acquired Hypothalamic ObesityNCT05774756 · Hypothalamic Obesity | Phase 3 | Active, not recruiting | Rhythm Pharmaceuticals, Inc. | 143 | 2025-03-18 |
| A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)NCT06760546 · Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia | Phase 3 | Recruiting | Rhythm Pharmaceuticals, Inc. | 39 | 2027-03-13 |
| Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)NCT07496463 · Pseudohypoparathyroidism Type 1a, Obesity | Phase 2 | Enrolling by invitation | Massachusetts General Hospital | 1 | 2027-04-30 |
Read the Setmelanotide profile →Search ClinicalTrials.gov ↗
Search terms: setmelanotide, RM-493.
KisspeptinReproductive4active4recruitingPhase 2top active phase15ever registeredInvestigational
Active trials, most advanced phase first.
| Trial | Phase | Status | Sponsor | Enrolment | Primary completion |
|---|---|---|---|---|---|
| Kisspeptin Administration Subcutaneously to Patients With Hypothalamic AmenorrheaNCT07224438 · Hypothalamic Amenorrhea, Hypogonadotropic Hypogonadism | Phase 2 | Recruiting | Stephanie B. Seminara, MD | 20 | 2030-05 |
| Kisspeptin Administration Subcutaneously to Patients With IHHNCT05896293 · Hypogonadotropic Hypogonadism | Phase 2 | Recruiting | Stephanie B. Seminara, MD | 36 | 2028-05 |
| Kisspeptin to Quantify GnRH Neuronal Function in Health and DiseaseNCT07224490 · Reproductive Disorder, Neurodegeneration, SARS-CoV 2 | Phase 1 | Recruiting | Stephanie B. Seminara, MD | 40 | 2030-05 |
| Reproductive Hormones During Sustained Administration of KisspeptinNCT02081924 · Fertility Disorders, Hypothalamic Dysfunction | Not applicable | Recruiting | Imperial College London | 76 | 2027-11-30 |
Read the Kisspeptin profile →Search ClinicalTrials.gov ↗
Search terms: kisspeptin.
LixisenatideMetabolic4active2recruitingPhase 4top active phase62ever registeredApproved Medicine
Active trials, most advanced phase first.
| Trial | Phase | Status | Sponsor | Enrolment | Primary completion |
|---|---|---|---|---|---|
| Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral AgentsNCT07307235 · Type 2 Diabetes | Phase 4 | Recruiting | Shanghai Zhongshan Hospital | 1,316 | 2027-06-30 |
| iGlarLixi CGM Study in Chinese T2D Individuals After OADsNCT06671587 · Type 2 Diabetes (T2D) | Phase 4 | Recruiting | Sanofi | 678 | 2026-09-18 |
| Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 DiabetesNCT07173712 · Type 2 Diabetes | Phase 4 | Not yet recruiting | Yanbing Li | 324 | 2027-06-30 |
| Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced DiabetesNCT07117240 · Steroid-Induced Diabetes, Steroid-Induced Hyperglycemia, Diabetes | Phase 4 | Enrolling by invitation | Medical University of Warsaw | 100 | 2028-02-09 |
Read the Lixisenatide profile →Search ClinicalTrials.gov ↗
Search terms: lixisenatide.
AbaloparatideOther3active0recruitingPhase 4top active phase18ever registeredApproved Medicine
Active trials, most advanced phase first.
| Trial | Phase | Status | Sponsor | Enrolment | Primary completion |
|---|---|---|---|---|---|
| Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab AloneNCT04467983 · Osteoporosis, Postmenopausal | Phase 4 | Active, not recruiting | Hospital for Special Surgery, New York | 70 | 2026-09-01 |
| Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion SurgeryNCT03841058 · Spinal Fusion | Phase 2 | Active, not recruiting | Hospital for Special Surgery, New York | 96 | 2027-02 |
| The Effect of Osteoporotic Medications on Vertebral Bone Quality ScoreNCT07587775 · Lumbar Degenerative Disease | Phase 2 | Enrolling by invitation | State University of New York at Buffalo | 60 | 2028-06-01 |
Read the Abaloparatide profile →Search ClinicalTrials.gov ↗
Search terms: abaloparatide, BA058.
ElamipretideOther3active2recruitingPhase 4top active phase24ever registeredApproved Medicine
Active trials, most advanced phase first.
| Trial | Phase | Status | Sponsor | Enrolment | Primary completion |
|---|---|---|---|---|---|
| Clinical Trial in Patients With Barth Syndrome- 4TAZPowerNCT07531251 · Barth Syndrome | Phase 4 | Recruiting | Stealth BioTherapeutics Inc. | 48 | 2029-09-30 |
| ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)NCT06373731 · Age Related Macular Degeneration (ARMD) | Phase 3 | Active, not recruiting | Stealth BioTherapeutics Inc. | 313 | 2027-08 |
| Study of Healthy Aging and Physical Function With ElamipretideNCT07275424 · Aging, Healthy | Phase 2 | Recruiting | David Marcinek | 30 | 2026-03-15 |
Read the Elamipretide profile →Search ClinicalTrials.gov ↗
Search terms: elamipretide, SS-31, MTP-131.
ExenatideMetabolic3active2recruitingPhase 4top active phase241ever registeredApproved Medicine
Active trials, most advanced phase first.
| Trial | Phase | Status | Sponsor | Enrolment | Primary completion |
|---|---|---|---|---|---|
| Exenatide Pharmacokinetics and Pharmacodynamics in Gestational DiabetesNCT05482789 · Gestational Diabetes | Phase 4 | Recruiting | Maisa N. Feghali, MD | 13 | 2025-12-31 |
| Brain Activation and Satiety in Children 2NCT04520490 · Childhood Obesity | Phase 3 | Active, not recruiting | Seattle Children's Hospital | 63 | 2025-08-21 |
| A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes MellitusNCT07347080 · T2DM | Early Phase 1 | Recruiting | The First Affiliated Hospital of Henan University of Science and Technology | 9 | 2026-08-31 |
Read the Exenatide profile →Search ClinicalTrials.gov ↗
Search terms: exenatide.
GonadorelinReproductive3active1recruitingPhase 3top active phase9ever registeredUnapproved
Active trials, most advanced phase first.
| Trial | Phase | Status | Sponsor | Enrolment | Primary completion |
|---|---|---|---|---|---|
| GnRH Therapy on Cognition in Down SyndromeNCT04390646 · Down Syndrome, Cognitive Decline, Alzheimer Disease, Early Onset | Phase 2/Phase 3 | Recruiting | Nelly Pitteloud | 56 | 2028-12 |
| Hormonal Mechanisms of Sleep Restriction - Axis StudyNCT03142893 · Sleep Restriction | Phase 1 | Active, not recruiting | Peter y. Liu | 80 | 2020-10-30 |
| Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal WomenNCT04037605 · Sleep Restriction | Early Phase 1 | Active, not recruiting | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | 5 | 2022-07-24 |
Read the Gonadorelin profile →Search ClinicalTrials.gov ↗
Search terms: gonadorelin.
PramlintideMetabolic3active1recruitingPhase 1top active phase53ever registeredApproved Medicine
Active trials, most advanced phase first.
| Trial | Phase | Status | Sponsor | Enrolment | Primary completion |
|---|---|---|---|---|---|
| Multi-Center Development of a Novel Diagnostic Test for Alzheimer's DiseaseNCT03560960 · Alzheimer Disease, Mild Cognitive Impairment | Early Phase 1 | Active, not recruiting | Boston University | 57 | 2026-11 |
| Postprandial Regulation of Bone Perfusion in Healthy IndividualsNCT07679516 · Healthy Adult Participants, Bone Physiology, Bone Blood Flow Regulation | Not applicable | Not yet recruiting | University of Copenhagen | 15 | 2028-05 |
| Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy HumansNCT07506369 · Obesity & Overweight | Not applicable | Recruiting | University Hospital, Gentofte, Copenhagen | 18 | 2026-10 |
Read the Pramlintide profile →Search ClinicalTrials.gov ↗
Search terms: pramlintide.
TesamorelinGrowth Hormone Axis3active3recruitingPhase 2top active phase18ever registeredApproved Medicine
Active trials, most advanced phase first.
| Trial | Phase | Status | Sponsor | Enrolment | Primary completion |
|---|---|---|---|---|---|
| Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIVNCT06554717 · HIV-1-infection, Frailty, Impaired Physical Function | Phase 2 | Recruiting | Massachusetts General Hospital | 100 | 2028-06-16 |
| Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)NCT07481734 · Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis, Hepatic Steatosis | Phase 2 | Recruiting | Hudson Biotech | 120 | 2027-02-14 |
| Tesamorelin to Improve Functional Outcomes After Peripheral Nerve InjuryNCT03150511 · Peripheral Nerve Injuries | Phase 2 | Recruiting | Johns Hopkins University | 36 | 2027-12 |
Read the Tesamorelin profile →Search ClinicalTrials.gov ↗
Search terms: tesamorelin, TH9507, Egrifta.
BPC-157Tissue repair research2active1recruitingPhase 2top active phase2ever registeredUnapproved
Active trials, most advanced phase first.
| Trial | Phase | Status | Sponsor | Enrolment | Primary completion |
|---|---|---|---|---|---|
| BPC 157 for Acute Hamstring Muscle Strain RepairNCT07437547 · Hamstring Muscle Strain, Skeletal Muscle Injury | Phase 2 | Recruiting | Hudson Biotech | 120 | 2027-02-14 |
| Impact of BPC-157 on Recovery Following Rotator Cuff Repair SurgeryNCT07803250 · Rotator Cuff Tear | Phase 1 | Not yet recruiting | University of Arkansas | 30 | 2027-08-01 |
Read the BPC-157 profile →Search ClinicalTrials.gov ↗
Search terms: BPC-157, BPC 157, PL 14736.
PemvidutideMetabolic2active1recruitingPhase 3top active phase5ever registeredInvestigational
Active trials, most advanced phase first.
| Trial | Phase | Status | Sponsor | Enrolment | Primary completion |
|---|---|---|---|---|---|
| Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASHNCT07795164 · Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Phase 3 | Recruiting | Altimmune, Inc. | 1,800 | 2028-12 |
| RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)NCT07009860 · Alcohol-associated Liver Disease | Phase 2 | Active, not recruiting | Altimmune, Inc. | 121 | 2027-09-30 |
Read the Pemvidutide profile →Search ClinicalTrials.gov ↗
Search terms: pemvidutide.
AfamelanotideSkin & Hair1active0recruitingPhase 3top active phase22ever registeredApproved Medicine
Active trials, most advanced phase first.
| Trial | Phase | Status | Sponsor | Enrolment | Primary completion |
|---|---|---|---|---|---|
| A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With VitiligoNCT06109649 · Vitiligo | Phase 3 | Active, not recruiting | Clinuvel, Inc. | 200 | 2025-12 |
Read the Afamelanotide profile →Search ClinicalTrials.gov ↗
Search terms: afamelanotide, Scenesse.
BremelanotideReproductive1active0recruitingPhase 2top active phase10ever registeredApproved Medicine
Active trials, most advanced phase first.
| Trial | Phase | Status | Sponsor | Enrolment | Primary completion |
|---|---|---|---|---|---|
| A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of ObesityNCT06565611 · Obesity | Phase 2 | Active, not recruiting | Palatin Technologies, Inc | 108 | 2025-02-05 |
Read the Bremelanotide profile →Search ClinicalTrials.gov ↗
Search terms: bremelanotide, PT-141, Vyleesi.
GHK-CuSkin & Hair1active1recruitingPhase 2top active phase1ever registeredUnapproved
Active trials, most advanced phase first.
| Trial | Phase | Status | Sponsor | Enrolment | Primary completion |
|---|---|---|---|---|---|
| Topical GHK-Cu Gel for Acute Skin Wound HealingNCT07437586 · Acute Standardized Cutaneous Wounds (Punch-biopsy Wounds) | Phase 2 | Recruiting | Hudson Biotech | 60 | 2027-02-14 |
Read the GHK-Cu profile →Search ClinicalTrials.gov ↗
Search terms: GHK-Cu, copper peptide, copper tripeptide.
Melanotan IISkin & Hair1active1recruitingPhase 2top active phase1ever registeredUnapproved
Active trials, most advanced phase first.
| Trial | Phase | Status | Sponsor | Enrolment | Primary completion |
|---|---|---|---|---|---|
| Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental VitiligoNCT07437560 · NonSegmental Vitiligo, Nonsegmental Vitiligo (Stable) | Phase 2 | Recruiting | Hudson Biotech | 60 | 2027-02-14 |
Read the Melanotan II profile →Search ClinicalTrials.gov ↗
Search terms: melanotan II, melanotan-II.
MOTS-cLongevity1active1recruitingPhase 2top active phase2ever registeredUnapproved
Active trials, most advanced phase first.
| Trial | Phase | Status | Sponsor | Enrolment | Primary completion |
|---|---|---|---|---|---|
| MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/ObesityNCT07505745 · Prediabetes, Insulin Resistance, Overweight/Obesity | Phase 2 | Recruiting | Hudson Biotech | 120 | 2027-02-14 |
Read the MOTS-c profile →Search ClinicalTrials.gov ↗
Search terms: MOTS-c, CB4211.
TB-500Tissue repair research1active1recruitingPhase 2top active phase1ever registeredUnapproved
Active trials, most advanced phase first.
| Trial | Phase | Status | Sponsor | Enrolment | Primary completion |
|---|---|---|---|---|---|
| TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVDNCT07487363 · Atherosclerotic Cardiovascular Diseases, Endothelial Dysfunction | Phase 1/Phase 2 | Recruiting | Hudson Biotech | 80 | 2027-02-14 |
Read the TB-500 profile →Search ClinicalTrials.gov ↗
Search terms: TB-500.
VIP (Vasoactive Intestinal Peptide)Other1active0recruitingPhase 2top active phase12ever registeredInvestigational
Active trials, most advanced phase first.
| Trial | Phase | Status | Sponsor | Enrolment | Primary completion |
|---|---|---|---|---|---|
| I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill PatientsNCT04488081 · COVID-19 | Phase 2 | Active, not recruiting | QuantumLeap Healthcare Collaborative | 1,500 | 2028-07-31 |
Read the VIP (Vasoactive Intestinal Peptide) profile →Search ClinicalTrials.gov ↗
Search terms: vasoactive intestinal peptide, aviptadil.
ArgirelineSkin & Hair0active0recruiting—top active phase3ever registeredUnapproved
No active interventional trials are registered under the search terms below. 3 past trials are on record.
Read the Argireline profile →Search ClinicalTrials.gov ↗
Search terms: argireline, acetyl hexapeptide-3, acetyl hexapeptide-8.
CJC-1295Growth Hormone Axis0active0recruiting—top active phase1ever registeredUnapproved
No active interventional trials are registered under the search terms below. 1 past trial is on record.
Read the CJC-1295 profile →Search ClinicalTrials.gov ↗
Search terms: CJC-1295, CJC 1295.
IpamorelinGrowth Hormone Axis0active0recruiting—top active phase2ever registeredUnapproved
No active interventional trials are registered under the search terms below. 2 past trials are on record.
Read the Ipamorelin profile →Search ClinicalTrials.gov ↗
Search terms: ipamorelin.
LarazotideOther0active0recruiting—top active phase13ever registeredInvestigational
No active interventional trials are registered under the search terms below. 13 past trials are on record.
Read the Larazotide profile →Search ClinicalTrials.gov ↗
Search terms: larazotide, AT-1001.
LL-37Immune0active0recruiting—top active phase2ever registeredUnapproved
No active interventional trials are registered under the search terms below. 2 past trials are on record.
Read the LL-37 profile →Search ClinicalTrials.gov ↗
Search terms: LL-37, cathelicidin.
No registered trials
We found no interventional trials of any status on ClinicalTrials.gov for these peptides. Claims about them rest on laboratory, animal or small unregistered human studies.
How to read this tracker
- A registered trial is not a result. Listing means a study was planned or started. It says nothing about whether the peptide works or is safe.
- "Active" covers recruiting, not yet recruiting, enrolling by invitation, and active but no longer recruiting.
- Counts depend on names. We match the intervention names listed for each peptide. Trials that use a different code name may be missed, and trials testing a combination are included.
- Related products are not counted. Full-length thymosin beta-4 medicines are not TB-500, and the prodrug fosgonimeton is not dihexa, so their trials are left out.
- Native hormones are excluded when their names match thousands of unrelated studies (GLP-1, GIP, PYY, ghrelin and insulin).
- Dose amounts in trial titles are shown as [dose], in line with our editorial policy.
Learn more in our guide to reading clinical trial registries. The counts are also part of our open peptide dataset.
Cite or link to this page
Reference
Inside Peptides. (2026, October 12). Peptide Clinical Trial Tracker. https://insidepeptides.org/tools/peptide-trial-tracker/HTML link
<a href="https://insidepeptides.org/tools/peptide-trial-tracker/">Peptide Clinical Trial Tracker</a> (Inside Peptides)